New Antibody JYB1907 Shows Tolerable Safety Profile
A phase I trial of this monoclonal antibody for solid tumors demonstrates no dose-limiting toxicities at tested levels.
Updated on Oct. 16, 2026 in Cancer
Live Poll
Should medical researchers prioritize the development of experimental monoclonal antibodies for treating advanced solid tumors?
Researchers have completed a first-in-human phase I dose-escalation trial for the monoclonal antibody JYB1907 in patients with advanced solid tumors. Results indicate the drug was well-tolerated at the doses tested, providing preliminary data for future combination therapy studies.
Why it matters
As clinicians look for new ways to treat advanced cancers, this phase I trial helps establish the initial safety and dosing framework for a new monoclonal antibody. By successfully identifying a manageable safety profile in humans, researchers can now progress toward testing the drug in combination with other treatments.
This phase I dose-escalation trial evaluated the monoclonal antibody JYB1907 in patients with advanced solid tumors. While researchers observed stable disease in 27.3% of participants, the results are preliminary and further clinical evaluation is required.
The details
Patients in the trial received intravenous doses of JYB1907 ranging from 0.5 to 30 mg/kg every 3 weeks to determine safety and pharmacokinetics. The study reported no dose-limiting toxicities, with a half-life of 8 to 16 days and no detectable anti-drug antibodies. Reported side effects were primarily grade 1-2, including elevated D-dimer, anemia, and increased C-reactive protein levels.
Timeline
April 20, 2023: The clinical trial was registered on ClinicalTrials.gov.
October 16, 2026: Article reporting study results was published.
Health Landscape
This study represents an early step in the development of new monoclonal antibodies for solid tumor oncology. It follows the established pattern of dose-escalation research used to move experimental therapies from laboratory investigation to initial human clinical settings.
This early-stage research is primarily relevant for patients considering clinical trial enrollment for advanced solid tumors. Questions about eligibility for such trials or the role of investigational monoclonal antibodies are important topics to discuss with your oncologist.
The takeaway
The phase I trial confirms that JYB1907 can be administered safely in humans at doses up to 30 mg/kg. Patients interested in how early-phase research impacts treatment options should consult their physician about current clinical trial opportunities for their specific condition.
Further reading
Learn more about ongoing developments in cancer treatment on our Cancer page.
More information
Review the full clinical trial registration record for more detailed study metrics.
Source note: This article includes information reported by Nature.
Live Poll
Should medical researchers prioritize the development of experimental monoclonal antibodies for treating advanced solid tumors?
